A5021732617- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Tuberculosis Research and Epidemiology
- HIV Research and Treatment
- Long-Term Effects of COVID-19
- Mycobacterium research and diagnosis
- Hepatitis C virus research
- Vector-Borne Animal Diseases
- Pharmacological Effects and Toxicity Studies
- Parasitic Diseases Research and Treatment
- COVID-19 Impact on Reproduction
- Parasites and Host Interactions
- Viral Infections and Outbreaks Research
- Infectious Diseases and Tuberculosis
- Immune Cell Function and Interaction
- Respiratory viral infections research
- Vaccine Coverage and Hesitancy
- HIV/AIDS drug development and treatment
- Viral Infections and Vectors
- Parasite Biology and Host Interactions
- Infectious Diseases and Mycology
- HIV/AIDS Research and Interventions
University of Turin
2022-2024
Ospedale Sacro Cuore Don Calabria
2024
Istituti di Ricovero e Cura a Carattere Scientifico
2024
Ospedale Amedeo di Savoia
2021-2022
To date, there is no severe acute respiratory syndrome coronavirus 2-(SARS-CoV-2)-specific prognostic biomarker available. We assessed whether SARS-CoV-2 cycle threshold (Ct) value at diagnosis could predict novel CoronaVirus Disease 2019 (COVID-19) severity, clinical manifestations, and six-month sequelae. Hospitalized outpatient cases were randomly sampled from the diagnoses of March 2020 data collected 6 months by interview regional database for COVID-19 emergency. Patients stratified...
A febrile man in Italy who had traveled to Cuba July 2024 was diagnosed with Oropouche fever. Reverse transcription PCR detected prolonged shedding of virus RNA whole blood, serum, urine, and semen. Sixteen days after symptom onset, replication-competent semen, suggesting risk for sexual transmission.
Background Longitudinal cohort data of patients with tuberculosis (TB) and coronavirus disease 2019 (COVID-19) are lacking. In our global study, we describe long-term outcomes affected by TB COVID-19. Methods We collected from 174 centres in 31 countries on all COVID-19 between 1 March 2020 30 September 2022. Patients were followed-up until cure, death or end time. All had COVID-19; for analysis purposes, deaths attributed to TB, both. Survival was performed using Cox proportional...
In a longitudinal study in first-level hospital Luanda, Angola, we found rifampin-resistant and multidrug-resistant tuberculosis (TB) 38 (8%, 95% CI 5.7-10.8) of 474 patients with no previous history TB. Of note, 2 (0.4%, 0.1-1.5) demonstrated pre-extensively drug-resistant
Background: Emerging evidence supports the “variolation hypothesis” in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), but derivative idea that viral load of index cases may predict disease severity secondary could be unsubstantiated. We assessed whether prevalence symptomatic infections, hospitalization, and deaths household contacts 2019 novel coronavirus (COVID-19) differed according to SARS-CoV-2 PCR cycle threshold (Ct) from nasal-pharyngeal swab at diagnosis linked cases....
Identifying determinants of the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) transmission in settings contagion is fundamental to inform containment strategies. We assessed SARS-CoV-2 cycle threshold value (Ct) from first diagnostic nasal-pharyngeal swab symptomatic index cases and which demographic or clinical characteristics among contacts are associated with risk within households.This a retrospective prevalence study on secondary (SC) household adult randomly...
Abstract Background Elite controllers are able to control viral replication without antiretroviral therapy. Exceptional elite do not show disease progression for more than 25 years. Different mechanisms have been proposed and several elements of both innate adaptive immunity implicated. Vaccines immune stimulating agents that can promote HIV-RNA transcription; transient plasma detectability has described within 7–14 days after different vaccinations. The most reliable mechanism involved in...
Central nervous system adverse events (AE) have been a cause of discontinuation dolutegravir-containing therapy, especially in combination with abacavir. The main aim the study was to evaluate whether switch bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) associated reduction severity and incidence neuropsychiatric symptoms compared continued dolutegravir/abacavir/lamivudine (DTG/ABC/3TC). DOBINeuro is randomized trial enrolling people living HIV (PLWH) treated DTG/ABC/3TC for...
Abstract Background Elite controllers are able to control viral replication without antiretroviral therapy. Exceptional elite do not show disease progression for more than 25 years. Different mechanisms have been proposed and several elements of both innate adaptive immunity implicated. Vaccines immune stimulating agents that can promote HIV-RNA transcription; transient plasma detectability has described within 7-14 days after different vaccinations. The most reliable mechanism involved in...
Background: No pathogen-specific prognostic biomarkers are yet available for SARS-CoV-2. We sought to assess whether SARS-CoV-2 cycle threshold value (Ct) at diagnosis may predict COVID-19 severity, clinical manifestations and 6-month sequelae. Methods: Hospitalised outpatient cases were randomly sampled from the diagnoses of March data collected after 6 months by interview regional database emergency. Patients stratified according their RNA-dependent-RNA-polymerase Ct in nasal-pharyngeal...